Hologic, Inc. logo
Hologic, Inc. (HOLX)
Compare

HOLX Cash Flow Statement

Operating, investing, and financing cash flow analysis

HOLX Quarterly Cash Flow Statement (USD)

Quarterly ReportTTM
12/27/2025
09/27/2025
06/28/2025
03/29/2025
12/28/2024
09/30/2024
06/29/2024
03/30/2024
Cash from Operations (CFO)
1.098B229.900M355.100M343.300M169.400M189.300M367.000M405.800M292.400M
543.900M179.100M187.300M194.900M-17.400M201.000M178.600M194.500M169.900M
Depreciation & Amortization
252.100M26.300M79.500M70.100M76.200M74.000M74.600M72.300M73.700M
81.100M26.900M12.300M13.500M28.400M30.100M13.200M14.600M25.800M
Change in Accounts Receivable
2.439B584.200M600.800M609.300M644.400M631.400M600.400M628.500M647.100M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
5.600M-51.200M73.000M80.200M-96.400M-77.200M106.900M54.400M34.600M
Cash from Investing
-98.100M-14.700M-30.400M-12.800M-40.200M-47.000M-30.300M-33.900M-28.000M
-321.200M0.000.001.300M-322.500M-300K-297.300M0.000.00
Cash from Financing
Debt Repayment
-235.800M0.000.00-35.600M-200.200M-517.300M-58.300M-100.300M-100K
0.000.000.000.000.000.000.000.000.00
999.600M215.200M324.700M330.500M129.200M142.300M336.700M371.900M264.400M
Net Change in Cash
385.900M208.500M224.300M305.700M-352.600M-378.100M-278.900M259.100M247.900M

HOLX Annual Cash Flow Statement (USD)

Annual Report
09/27/2025
09/30/2024
09/30/2023
09/30/2022
09/30/2021
09/30/2020
09/30/2019
09/30/2018
Cash from Operations (CFO)
1.057B1.285B1.051B2.126B2.330B896.600M649.500M732.900M
565.700M789.500M456.000M1.302B1.871B1.115B-40.200M-111.300M
Depreciation & Amortization
299.800M309.000M323.400M430.100M406.900M376.000M463.000M480.300M
84.300M82.300M79.600M66.700M65.000M83.300M62.000M65.000M
Change in Accounts Receivable
600.800M600.400M625.600M617.600M942.700M1.029B648.700M579.200M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-20.400M84.100M3.000M454.200M-34.400M-636.300M-161.300M-26.200M
Cash from Investing
-137.000M-140.200M-150.200M-127.200M-177.700M-156.400M-113.600M-105.600M
-321.500M-297.300M-5.000M-158.600M-1.165B19.900M-128.800M-76.500M
Cash from Financing
Debt Repayment
-752.900M-835.100M-498.800M-542.100M-457.300M-653.600M-200.100M-275.800M
0.000.000.000.000.000.000.000.00
920.100M1.145B901.000M1.998B2.153B740.200M535.900M627.300M
Net Change in Cash
-200.700M-595.500M416.200M1.169B469.300M99.200M-64.900M126.100M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Hologic, Inc.

Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.

Marlborough, MA
7,063 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Paul Malenchini